

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
ATTORNEY DOCKET NO. 039386-0101 (FORMERLY PF-0346-2 RCE)

Applicant: Jennifer HILLMAN et al.
Title: T-CELL RECEPTOR BETA-LIKE PROTEIN
Appl. No.: 09/405,940
Filing Date: 09/27/1999
Examiner: Gerald R. Ewoldt
Art Unit: 1644

REVOCATION OF POWER OF ATTORNEY AND
APPOINTMENT OF NEW ATTORNEYS

Sir:

The undersigned has reviewed all the documents in the chain of title of the above-identified patent application and, to the best of undersigned's knowledge and belief, title is in the assignee identified below.

Incyte Corporation, formerly known as Incyte Genomics, Inc., also formerly known as Incyte Pharmaceuticals, Inc., having a principal place of business located at 3160 Porter Drive, Palo Alto, California 94304, certifies that it is the assignee and owner of the entire right, title and interest in, to, and under the invention described and claimed in the above-identified application by virtue of an Assignment recorded at Reel 008648, Frame 0077, hereby revokes all previous powers of attorney and appoints those practitioners under Customer No. 22428 as attorneys/ agents with full power of substitution to prosecute this application and to transact all business in the Patent and Trademark Office in connection therewith.

Atty. Dkt. No. 039386-0101
(Formerly PF-0346-2 RCE)

Please direct all correspondence to:

Michele M. Simkin, Esq.
Reg. No. 34,717
Customer No.: 22428
Foley & Lardner LLP
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109

and direct all telephone calls and facsimile transmissions to: Foley & Lardner LLP; Phone:Tel:
(202) 672-5300 Fax: (202) 672-5399 The undersigned (whose title is supplied below) is
empowered to act on behalf of the assignee.


I hereby declare that all statements made herein are of my own knowledge are true and
that all statements made on information and belief are believed to be true, and further that these
statements are made with the knowledge that willful false statements and the like so made are
punishable by fine of imprisonment, or both, under Section 1001, Title 18, of the United States
Code, and that such willful false statements may jeopardize the validity of the patent.

INCYTE CORPORATION

Date:

June 28, 2004

By:



Patricia Anne Schreck
Executive VP, General Counsel